T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.44 SGD -2.22% Market Closed
Market Cap: 584.2m SGD
Have any thoughts about
Talkmed Group Ltd?
Write Note

Net Margin
Talkmed Group Ltd

35%
Current
39%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35%
=
Net Income
27.7m
/
Revenue
79.1m

Net Margin Across Competitors

Country SG
Market Cap 583.7m SGD
Net Margin
35%
Country US
Market Cap 91.8B USD
Net Margin
1%
Country US
Market Cap 87.7B EUR
Net Margin
1%
Country US
Market Cap 73B USD
Net Margin
1%
Country DE
Market Cap 24.9B EUR
Net Margin
3%
Country US
Market Cap 20.1B USD
Net Margin
3%
Country DE
Market Cap 18.8B EUR
Net Margin
-2%
Country US
Market Cap 18.3B USD
Net Margin
9%
Country US
Market Cap 13.7B USD
Net Margin
7%
Country DE
Market Cap 12.4B EUR
Net Margin
3%
Country AU
Market Cap 13.4B AUD
Net Margin
6%
No Stocks Found

Talkmed Group Ltd
Glance View

Market Cap
583.7m SGD
Industry
Health Care

TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).

5G3 Intrinsic Value
0.31 SGD
Overvaluation 30%
Intrinsic Value
Price
T

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
35%
=
Net Income
27.7m
/
Revenue
79.1m
What is the Net Margin of Talkmed Group Ltd?

Based on Talkmed Group Ltd's most recent financial statements, the company has Net Margin of 35%.